Multicenter clinical trial of acute lymphoblastic leukemia in elder children and adolescents.
10.3760/cma.j.issn.0253-2727.2018.09.003
- Author:
Na ZHANG
1
;
Shu Hong SHEN
;
Ning Ling WANG
;
Hong LI
;
Jing Wei YANG
;
Jing bo SHAO
;
Hui JIANG
1
;
Jing Yan TANG
2
Author Information
1. Department of Hematology/Oncology, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai 200040, China.
2. Department of Hematology/Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University school of Medicine, Shanghai 200127, China.
- Publication Type:Journal Article
- Keywords:
Adolescent;
Children;
Event-free survival;
Leukemia, lymphoblastic
- MeSH:
Adolescent;
Antineoplastic Combined Chemotherapy Protocols;
Child;
Disease-Free Survival;
Humans;
Male;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Prognosis;
Remission Induction;
Risk Factors;
Translocation, Genetic
- From:
Chinese Journal of Hematology
2018;39(9):717-723
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the clinical characteristics and long-term outcomes with multicenter study for acute lymphoblastic leukemia (ALL) in children over 10 years old and adolescents. Method: Newly diagnosed ALL patients aged from 10 to 18 years old in three hospitals were included in the study from May 1(st) 2005 to April 30(th) 2015. They were received ALL-2005/2009 protocol following up to December 31(st) 2016. The clinical characteristics, outcomes and the prognostic analysis were evaluated between the two protocols. Results: Totally, 237 patients were involved in the study, 76 cases for ALL-2005 and 161 cases for ALL-2009 protocol. Complete remission (CR) after induction therapy was 94.5%. 64 (28.6%) patients relapsed with a median time of 14.5 months and 70 (29.5%) patients passed away during the following time. In long-term follow-up, the 5-year event-free survival (EFS) and 5-year overall survival (OS) of ALL patients were (63.1±3.3)% and (68.4±3.2)%. The 7-year EFS and OS were (61.0±3.5)% and (67.6±3.3)%.The 5-year EFS of intermediate risk group in ALL-2005 and ALL-2009 protocol were (73.6±6.1)% and (71.7±4.3)% with no difference (χ(2)=0.064, P=0.801). The 5-year EFS of high risk group in two protocols were (27.6±9.6)% and (33.9±9.3)%, showing no significant difference (χ(2)=0.296, P=0.586). Five years relapsed rate of two protocols were (33.8±5.7)% and (32.6±4.1)% with no difference (χ(2)=0.055, P=0.815). The mortalities were 36.8% and 29.8% separately (χ(2)=2.869, P=0.090). Univariate analysis indicated that age, male, risk, BCR/ABL translocation/t(9;22) and resistant to induction were risk prognostic factors in long-term survival (χ(2)=4.764, 4.796, 46.410, 9.560, 25.450; P=0.029, 0.029, <0.001, 0.049, <0.001). Cox multivariate analysis showed male, risk and resistant to induction were independent risk prognostic factors (RR=1.790, 2.727, 2.719; P=0.021, 0.000, 0.012). Conclusion: Protocol ALL-2009 enhanced the chemotherapy intensity in intermediate risk group with no benefit of survival. BCR-ABL fusion or t(9;22) translocation was still the risk factor of prognosis. TKI inhibitor used in these patients could improve survival. EFS rate was increased a little and death rate was decreased in ALL-2009 protocol with no significant lower relapsed rate comparing with ALL-2005 protocol.
